Does Rallies show Form 4 insider transactions for BMEA?

Yes. Rallies tracks BMEA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BMEA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BMEA. It does not provide personalized investment advice.

BMEA (Biomea Fusion, Inc. Common Stock) Stock Analysis - Insider Trades

Biomea Fusion, Inc. Common Stock (BMEA) is a publicly traded Healthcare sector company. As of May 21, 2026, BMEA trades at $1.38 with a market cap of $90.37M and a P/E ratio of -1.09. BMEA moved +9.84% today. Year to date, BMEA is +3.91%; over the trailing twelve months it is -15.29%. Its 52-week range spans $0.87 to $13.07. Analyst consensus is buy with an average price target of $7.20. Rallies surfaces BMEA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BMEA stock inside the company?

Recent BMEA insider activity includes Erdtmann Rainer M bought 30.00K, Hitchcock Michael J.M. bought 100.00K, Erdtmann Rainer M bought 10.00K, Erdtmann Rainer M bought 40.00K, and Hitchcock Michael J.M. bought 10.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BMEA Key Metrics

Key financial metrics for BMEA
Metric	Value
Price	$1.38
Market Cap	$90.37M
P/E Ratio	-1.09
EPS	$-1.18
Dividend Yield	0.00%
52-Week High	$13.07
52-Week Low	$0.87
Volume	987
Avg Volume	0
Revenue (TTM)	$1.86M
Net Income	$-61.80M
Gross Margin	0.00%

Recent BMEA Insider Trades

Erdtmann Rainer M bought 30.00K (~$43.00K) on Dec 11, 2025.
Hitchcock Michael J.M. bought 100.00K (~$99.18K) on Dec 2, 2025.
Erdtmann Rainer M bought 10.00K (~$10.50K) on Dec 1, 2025.
Erdtmann Rainer M bought 40.00K (~$44.05K) on Nov 28, 2025.
Hitchcock Michael J.M. bought 10.00K (~$100.60K) on Sep 30, 2024.

Latest BMEA News

Biomea Fusion Posts $12.4M Q1 Loss on $45.1M Cash Runway, Advances Clinical Trials — May 11, 2026
Biomea Fusion to Present Three Late-Breaking Icovamenib Posters on T1D and T2D — May 5, 2026
Biomea Fusion’s Icovamenib Boosts C-Peptide 52% at Week 12, Durable to Week 52 — Apr 27, 2026
Biomea Fusion Doses First Patient in 60-Subject Phase II Trials with Q4 2026 Readout — Mar 31, 2026
Biomea Fusion Initiates Two Phase II Diabetes Trials, Projects Q1 2027 Cash Runway — Mar 24, 2026

BMEA Analyst Consensus

6 analysts cover BMEA: 0 strong buy, 5 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.20.

Common questions about BMEA

Who is trading BMEA stock inside the company?: Recent BMEA insider activity includes Erdtmann Rainer M bought 30.00K, Hitchcock Michael J.M. bought 100.00K, Erdtmann Rainer M bought 10.00K, Erdtmann Rainer M bought 40.00K, and Hitchcock Michael J.M. bought 10.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BMEA?: Yes. Rallies tracks BMEA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BMEA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BMEA. It does not provide personalized investment advice.